logo
Book a meeting
Regenxbio

Regenxbio

Biotechnology, 9600 Blackwell Rd Ste 210, Rockville, Maryland, 20850, United States, 10001+ Employees

regenxbio.com/home

  • twitter

phone no Phone Number: +13*********

Who is REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technol...

Read More

lock icon Get Full Access
map
  • 9600 Blackwell Rd Ste 210, Rockville, Maryland, 20850, United States Headquarters: 9600 Blackwell Rd Ste 210, Rockville, Maryland, 20850, United States
  • 2008 Date Founded: 2008
  • 10001+ Employees: 10001+
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from REGENXBIO

Regenxbio Org Chart and Mapping

Employees
Robert Haynes

Robert Haynes

Senior Director, Global Product, Market Planning

See Full Org Chart arrow
email-formate-icon
View Email Formats for Regenxbio
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Regenxbio

Answer: Regenxbio's headquarters are located at 9600 Blackwell Rd Ste 210, Rockville, Maryland, 20850, United States

Answer: Regenxbio's phone number is +13*********

Answer: Regenxbio's official website is https://regenxbio.com/home

Answer: Regenxbio's revenue is $50 Million to $100 Million

Answer: Regenxbio's SIC: 2836

Answer: Regenxbio's NAICS: 541714

Answer: Regenxbio has 10001+ employees

Answer: Regenxbio is in Biotechnology

Answer: Regenxbio contact info: Phone number: +13********* Website: https://regenxbio.com/home

Answer: REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access